CervoMed (NASDAQ:CRVO - Get Free Report) is expected to announce its Q1 2025 earnings results before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.60) per share and revenue of $1.70 million for the quarter.
CervoMed (NASDAQ:CRVO - Get Free Report) last announced its earnings results on Monday, March 17th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.13). CervoMed had a negative net margin of 118.68% and a negative return on equity of 44.11%. The firm had revenue of $2.16 million during the quarter, compared to analyst estimates of $1.51 million. On average, analysts expect CervoMed to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
CervoMed Stock Down 3.1 %
CRVO traded down $0.31 during trading hours on Tuesday, hitting $9.64. 57,464 shares of the company's stock were exchanged, compared to its average volume of 3,504,094. The stock's 50-day moving average is $8.09 and its two-hundred day moving average is $6.56. CervoMed has a 1-year low of $1.80 and a 1-year high of $25.69. The stock has a market cap of $83.90 million, a price-to-earnings ratio of -4.75 and a beta of -0.23.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on CRVO. Jones Trading raised CervoMed from a "hold" rating to a "buy" rating and set a $15.00 price target on the stock in a research report on Thursday, March 13th. Canaccord Genuity Group lifted their price target on shares of CervoMed from $12.00 to $21.00 and gave the company a "buy" rating in a report on Tuesday, March 18th. Brookline Capital Management upgraded shares of CervoMed from a "hold" rating to a "strong-buy" rating in a report on Tuesday, March 11th. Roth Mkm raised their price target on shares of CervoMed from $15.00 to $20.00 and gave the stock a "buy" rating in a report on Tuesday, March 18th. Finally, Chardan Capital raised CervoMed from a "neutral" rating to a "buy" rating and set a $14.00 target price for the company in a research note on Thursday, March 13th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $27.50.
Read Our Latest Stock Report on CervoMed
About CervoMed
(
Get Free Report)
CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CervoMed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CervoMed wasn't on the list.
While CervoMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
